课题基金 / 基金详情

Task V33: Manufacturing of Master Cell Bank Production and Formulation Development for Antibacterial resistance

Task V33: Manufacturing of Master Cell Bank Production and Formulation Development for Antibacterial resistance
任务V33:主细胞库生产的制造和抗菌药物耐药性的制剂开发
批准号:
10937160
负责人:
CHRISTINE MEYER
金额:
$44.33万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-26 至 2024-09-25

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and feasibility assessments; product optimization; product development and cGMP compliant manufacture for Phase I/II clinical studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against antibacterial resistant pathogens. This contract also provides for manufacture of vaccines, vaccine components including adjuvants, vaccine delivery systems, other biologics, and challenge material.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金